Hertraz 150mg injection online - Trastuzumab|
Myapplepharma
Hertraz 150mg is a group of medicines which belongs to
anti neoplastic medication. Hertraz 150mg is a chemotherapy drug. It is
recommended that Hertraz 150mg be administered under the guidance of a qualified physician
experienced in the use of cancer chemotherapeutic agents.
USES
- The Hertraz 150mg injection is
used alone or combination with other medicine for the treatment in
patients who suffering from metastatic breast cancer.
- The drug also indicated with combination of other
medicine for the treatment of certain types of stomach or esophagus cancer
in some persons.
WORK AS
- Different type of breast cancer cells has a higher than
normal level of a protein called HER2 (human epidermal growth factor
receptor 2) on their surface. These HER2 receptors get signals which
stimulate the tumor cells to develop and reproduce. But breast cancer
cells with too many HER2 receptors can Choice too many growth signals and
so start developing and proliferating too much and too fast.
- Hertraz acts
by adhere itself to the HER2 receptors on the surface of breast cancer
cells and stopping them from collecting growth signals. By stopping the
signals, Hertraz can slow or inhibit the growth of the breast cancer and
the drug is an immune targeted therapy. In addition to inhibiting HER2
receptors, Trastuzumab can
also help to fight against breast cancer by attentive the immune system to
damage the cancer cells onto which it is attached.
- The Hertraz 150mg injection should
not mix with other drugs and do not administer as an intravenous push or
bolus.
- Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine
Adjuvant treatment,
breast cancer:
The drug given according to one of the following doses and
schedules for a 52 weeks total of trastuzumab treatment:
- During combination with paclitaxel, docetaxel, or
docetaxel /Carboplatin:
- Starting dose of 4 mg/kg as an IV (intravenous
infusion) over 90 minutes followed at 2 mg/kg as an IV (intravenous
infusion) over 30 minutes weekly during treatment of chemotherapy given
with paclitaxel or docetaxel for first 12 weeks or 18 weeks
(docetaxel/carboplatin) The Hertraz dose for One week following the last
weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion)
over 30 to 90 minutes every three weeks.
The injection given as a
single agent within three weeks following completion of multi-modality,
anthracycline-based chemotherapy regimens:
- For an intravenous infusion over 90 minutes: Initial
dose at 8 mg/kg
- Successive doses at 6 mg/kg over 30 to 90 minutes every
three weeks as an intravenous infusion.
- Adjuvant treatment stretching beyond one year is not
recommended.
Metastatic Treatment,
Breast Cancer:
- Hertraz 150mg administrated
alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as
a 90-minute intravenous infusion continued by successive once weekly doses
of 2 mg/kg as 30-minute intravenous infusions until disease development.
Metastatic Gastric Cancer:
- Hertraz 150mg injection administrated
at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion
continued by successive doses of 6 mg/kg as an intravenous infusion over
30 to 90 minutes every three weeks until disease development.
Embryo fetal damage
Hertraz 150mg is contraindicated to pregnancy period.
Avoid becoming pregnancy during this therapy. Use efficient contraceptives
during treatment.
Cardiomyopathy
Patient getting Hertraz 150mg have increased risk of exposing to cardiac
disorders. Provide alternative therapy management In serious condition,
treatment should be discontinuing.
Pulmonary toxicity
Some serious fatal cases
of pulmonary toxicity occur during Hertraz 150mg treatment.
Infusion reactions
During Hertraz 150mg treatment some life-threatening infusion
reactions are produced. In serious infusion reactions, Stop the Hertraz 150mg treatment permanently. Patient should be
treated with premedication before starting the infusion to overcome the such
problem, During Hertraz treatment. Use with Caution.
Therapy induced neutropenia
Higher incidence of
neutropenia occurs during Hertraz 150mg treatment.
DRUG INTERACTION
- In some phenomenal condition, patient should get
anthracycline, in that situation patient’s cardiac function should be
checked carefully with regular intervals.
- Do not take anthracycline treatment for 7 months after
stopping the Hertraz 150mg treatment.
- Hertraz 150mg injection interaction with anthracycline after ending of
Hertraz 150mg treatment may have a chance of getting cardiac problem. This
side effects occur because of Trastuzumab great disaster period is depends
on population PK analysis.
CONTRAINDICATION
Probably no
contraindicated occurs. The patients are contraindicated to the component
present in the Hertraz 150mg injection, Hence Hypersensitivity reactions are
occurring.
STORAGE
- Store the drug at 2℃
to 8℃ (refrigerator temperature) Protected the vial away
from heat & light Stored at 2℃
to 8℃ for 28 days after reconstitution Stored Hertraz 150mg
diluted bag at 2℃ to 8℃
for 24 hours.
MISSED DOSE
The drug Missing doses
can decrease their usefulness and raises the probability of developing drug
resistance, that makes this drug lose their potency. For best results, it is
important to accept each scheduled dose of Trastuzumab medication
as instructed. If you miss a dose, leave the missed dose and continue with your
regular dosing schedule. Do not have two doses to make up for a missed one. If
you are not sure about what to do after missing a dose, the take advice with
doctor or pharmacist.
SIDE EFFECTS
Common side effects:
- Redness at injection site (IV)
- Muscle/joint/back pain
- Insomnia
- Tiredness
- Mild skin rash
- Stuffy nose
- Sinus pain
Serious side effects:
- Increased coughing
- Sudden unexplained weight gain
- Unusual tiredness
- Easy bruising or bleeding
- Fast or pounding heartbeat
- Increased coughing
CONTACT DETAILS
Phone : 9987711567
Email : applepharmaceutical@gmail.com
Email : info@myapplepharma.com
Comments
Post a Comment